Moleculin Biotech
MBRX
18 hedge funds and large institutions have $8.88M invested in Moleculin Biotech in 2021 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 4 increasing their positions, 0 reducing their positions, and 4 closing their positions.
884% more capital inflows, than outflows
Capital inflows: $9.38M | Capital outflows: $954K
175% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 4
64% more funds holding
Funds holding: 11 → 18 (+7)
3.47% more ownership
Funds ownership: 4.1% → 7.57% (+3.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sio Capital Management
New York
|
+$4.69M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.8M |
| 3 |
BlackRock
New York
|
+$1.14M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$586K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$183K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$756K |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$105K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$29K |
| 4 |
HighTower Advisors
Chicago,
Illinois
|
-$21K |
| 5 |
Levy Wealth Management Group
Philadelphia,
Pennsylvania
|
-$11K |
MBRX Hedge Fund Activity: Q1 2021 in Review
18 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q1 2021, worth a combined $8.88M — up 336% from $2.04M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new MBRX positions and 4 closed out — a net gain of 7 holders — while 4 added to existing stakes and 0 trimmed.
The largest buyer was Sio Capital Management, opening a new position worth an estimated $4.69M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $756K sold.
- 18 institutional investors held Moleculin Biotech (MBRX) as of Q1 2021, up from 11 in Q4 2020.
- Funds reported $8.88M of Moleculin Biotech stock for Q1 2021, up 336% quarter-over-quarter.
- 11 funds opened new Moleculin Biotech positions in Q1 2021 and 4 closed out, a net change of +7 holders.
- The largest Moleculin Biotech buyer in Q1 2021 was Sio Capital Management, an estimated $4.69M added.
- The largest Moleculin Biotech seller in Q1 2021 was Renaissance Technologies, an estimated $756K sold.
Based on aggregated 13F filings for Q1 2021.